Zimmer Biomet has beaten analyst expectations by generating $1.976 billion in net sales during the first quarter. President and CEO Bryan Hanson said the company still maintains its short-term priorities, namely "supply recovery shifting to supply efficiency; quality remediation moving to best-in-class quality; new product launches shifting to providing customer-centric solutions; and continued optimization of our talent structure; and then finally, relentlessly driving and winning One ZB mission and culture."
Zimmer Biomet surpasses Q1 estimates, maintains short-term priorities
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.